Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 juin 2017 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clinical Immunology Societies (FOCIS) Conference

OSE-127 Blocks Pathological Homing of Human T Lymphocytes to Inflamed ColonEx vivo, OSE-127 Reduces Production of Gamma Interferon by Human Proinflammatory Bowel T lymphocytes in Patients’ Biopsies ...
14 juin 2017 13h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Results of 2017 Annual Meeting of Shareholders

NANTES, France, June 14, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173); (Mnémo:OSE) announces that all the resolutions submitted to a vote at the Combined General...
12 juin 2017 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New York

NANTES, France, June 12, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173);(Mnémo:OSE) today announced that the Company has entered into a multi-year research collaboration on...
22 mai 2017 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists

NANTES, France, May 22, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173); (Mnémo:OSE) announced today the appointment of Aurore Morello, Ph.D., as Immunology Researcher, and...
18 mai 2017 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum

NANTES, France, May 18, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173) (Mnémo:OSE) announced today that the Company will present at the upcoming “Annual Sachs...
15 mai 2017 12h15 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress,” London, May 15-16, 2017

NANTES, France, May 15, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) announced today that the Company presented in oral session significant data on Selective...
05 avr. 2017 02h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presented New Data at AACR* Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Antitumoral Potent T Memory Response

NANTES, France, April 05, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173) (Mnémo:OSE) announced today that the Company presented significant results at the AACR* meeting in...
28 mars 2017 12h00 HE | Source: OSE Immunotherapeutics

2016 Results: Significant Milestones, First Profit, More Growth to Come

Two global license and license option agreements signed with Janssen Biotech in July and with Servier in December for maximum cumulated amounts worth > €400 million* plus royaltiesAn international...
21 févr. 2017 16h36 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM) at the 24th Molecular Med TRI-CON 2017 Meeting

Session “Cancer Immunotherapy” San Francisco, February 20-22, 2017 NANTES, France, Feb. 21, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced...
27 déc. 2016 18h01 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7

NANTES, France and PARIS, Dec. 27, 2016 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE), today announced that the company has entered into a worldwide license option...